Related Experiment Video

Updated: May 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

James L Gulley, Susan F Leitman, William Dahut

    Journal of the National Cancer Institute
    |July 25, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
    09:04

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

    Published on: March 7, 2025

    Related Experiment Videos

    Last Updated: May 20, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
    09:04

    Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

    Published on: March 7, 2025

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

    Articles linked to this work by shared authors, journal, and citation graph.

    Early termination of clinical trials enrolling patients with breast cancer: Reasons, determinants, and temporal patterns.

    Breast (Edinburgh, Scotland)·2026

    Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.

    BJU international·2026

    Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance.

    Journal for immunotherapy of cancer·2026

    The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression.

    Cancer medicine·2026

    Erratum to 'Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer' [JTO Clinical and Research Reports 7 (2026) 101019].

    JTO clinical and research reports·2026

    Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.

    Oncoimmunology·2026

    Effects of private health insurance coverage gains on colorectal cancer outcomes: a modeling study.

    Journal of the National Cancer Institute·2026

    Novel framework for the validation of intermediate clinical endpoints in oncology real-world data.

    Journal of the National Cancer Institute·2026

    Time trends of human papillomavirus-attributable head and neck cancers: the BROADEN study.

    Journal of the National Cancer Institute·2026

    Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

    Journal of the National Cancer Institute·2026

    Colonoscopy screening outcomes in Lynch syndrome and differential colorectal cancer paths among MLH1/MSH2 carriers.

    Journal of the National Cancer Institute·2026

    Identification of prediagnostic proteomic biomarkers for colon and rectal cancer in 3 prospective cohorts.

    Journal of the National Cancer Institute·2026

    The soluble HLA repertoire captures neoantigenic, cryptic, and tumour-associated peptides in melanoma.

    Molecular & cellular proteomics : MCP·2026

    Inflammatory Breast Cancer-The Evolution of Diagnosis and Modern Clinical Management.

    JCO oncology practice·2026

    Engineering Subcutaneous Ectopic Tertiary Lymphoid Structures as Personalized Immune-Activation Niches for Cancer Immunotherapy.

    ACS applied bio materials·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us